Introduction
Cytochrome P450 enzymes are involved in initial oxidation, reduction or alkylation of xenobiotics that convert inactive carcinogens into active electrophiles which have the capacity to interact with biological molecules. CYP genes convert several anti-neoplastic agents into intermediate reactive metabolites, some of which can damage DNA. [1] Polymorphisms in the CYP genes have been associated with increased or decreased risk of certain cancers, because of extensive or poor metabolism of carcinogens or drugs. [2] The genetic variations which result in altering the activity of these enzymes had been found to be associated with the risk of developing secondary cancers and t -AML/t-MDS. [3] CYP3A5 family plays a significant role in the metabolism of more than 100 different drugs, carcinogens and toxic chemicals. [4] The CYP3A5 gene is located on chromosome 7q21.1. CYP3A5 was observed to be an important genetic contributor to inter individual differences in CYP3A-dependent drug metabolism. Loss of CYP3A5 expression was mainly conferred by a single nucleotide polymorphism at 6986A>G (CYP3A5*3). This SNP produces a cryptic splice site resulting in the inclusion of exon 3B followed by splicing which consequently introduces a stop codon. As a result, CYP3A5*3 protein is truncated with greatly reduced enzyme activity in homozygous CYP3A5*3 individuals.
In the present study, attempt has been made to identify the association of CYP3A5*3 polymorphism with the development of acute leukemia. 
Materials and Methods

Study subjects
The study includes 289 acute leukemia cases comprising of 145 acute lymphocytic leukemia (ALL), 144 acute myeloid leukemia (AML) and 241 control samples. oncologist. Genomic DNA was isolated by using saltingout method. [5] Restriction fragment length polymorphism Chi square values and Odds ratios were calculated to test the significance of genotype association with the occurrence of acute leukemia. t test was done to test the significance of association of clinical variables with the risk of acute leukemia. All the P values were two sided and the level of significance was taken as P <0.05.
Results
CYP3A5*3 homozygous genotype (3/3) and 3 allele frequency were significantly elevated in both ALL and AML groups as compared to control group. The genotype distribution of CYP3A5*3 polymorphism in AML group did not deviate from Hardy-Weinberg equilibrium, whereas the control group showed significant deviation from Hardy-Weinberg equilibrium (χ 2 -28.1) [ Table 1 ]. Odds ratios were significant for 1/1 vs 1/3 and 1/3 vs 3/3 groups among AML cases and for 1/1 vs 1/3 and 1/1 vs 3/3 groups among ALL cases when compared with controls [ Table 2 ].
When the genotype data was analyzed with respect to epidemiological variables like sex, age at onset, none of the variables showed significant association with CYP3A5*3 [ Tables 3-6 ]. However, 3/3 genotype frequency was found to be elevated among ALL patients with age at onset >20 years (28.2%) as compared to those with age at onset <10 years (14.3%) [ Table 5 ]. In AML, 3/3 genotype frequency was elevated considerably in early age at onset group (41.7%) as compared to later age at onset group (29.7%) [ Table 6 ]. Table 9 ].
There was no variation with respect to platelet count, Hb in both ALL and AML patients. Previous studies reported the lack of association of CYP3A5*3 with development of myeloid leukemia (CML, AML). [8] No significant association was reported between CYP3A5*3 polymorphism and morbidity of acute leukemia patients, but it was closely associated with the chemotherapeutic effect and prognosis. [9] The results also indicated that selection might be operating in the population against *3 allele, since loss of CYP3A5 enzyme activity is associated with defective detoxification of xenobiotics. These selective forces might be responsible for deviation from Hardy-Weinberg equilibrium in the control group. Hence, increased frequency of *3 allele in disease group and also the lack of deviation of the same from Hardy-Weinberg equilibrium indicated the importance of selection in elimination of ineffective allele. However, sample size and method of sampling also contribute to deviation from equilibrium.
Discussion
In conclusion, our results suggested that the CYP3A5*3 polymorphism might confer the risk to develop ALL or AML. The 3/3 genotype can be considered as a risk genotype to develop acute leukemia and also 
